Shanghai Kaibao Pharmaceutical Co (SZSE:300039) Accounts Payable & Accrued Expense : ¥326 Mil (As of Mar. 2024)

View and export this data going back to 2010. Start your Free Trial

What is Shanghai Kaibao Pharmaceutical Co Accounts Payable & Accrued Expense?

Shanghai Kaibao Pharmaceutical Co's quarterly accounts payable & accrued expense declined from Sep. 2023 (¥355 Mil) to Dec. 2023 (¥281 Mil) but then increased from Dec. 2023 (¥281 Mil) to Mar. 2024 (¥326 Mil).

Shanghai Kaibao Pharmaceutical Co's annual accounts payable & accrued expense increased from Dec. 2021 (¥180 Mil) to Dec. 2022 (¥244 Mil) and increased from Dec. 2022 (¥244 Mil) to Dec. 2023 (¥281 Mil).

Shanghai Kaibao Pharmaceutical Co Accounts Payable & Accrued Expense Historical Data

The historical data trend for Shanghai Kaibao Pharmaceutical Co's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Kaibao Pharmaceutical Co Accounts Payable & Accrued Expense Chart

Shanghai Kaibao Pharmaceutical Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

235.32

199.84

179.73

243.68

280.77

Shanghai Kaibao Pharmaceutical Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															361.40	385.37	355.47	280.77	326.12

Shanghai Kaibao Pharmaceutical Co Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Shanghai Kaibao Pharmaceutical Co (SZSE:300039) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shanghai Kaibao Pharmaceutical Co Ltd (SZSE:300039) » Definitions » Accounts Payable & Accrued Expense

Traded in Other Exchanges

N/A

Address

88 Chengpu Road, Shanghai Industrial Comprehensive Development Zone, Shanghai, CHN, 201401

Website

http://www.xykb.com

Shanghai Kaibao Pharmaceutical Co Ltd is a China-based pharmaceutical company. It is engaged in research, development, production, and sales of modern Chinese medicine. The company produces traditional Chinese medicines in the form of solid dosage, oral liquids, and small volume injections. Its main product is Tanreqing injection is mainly used for pneumonia, acute and chronic bronchitis and upper respiratory tract infection.

Executives

Liu Shao Yong	Supervisors
Ren Li Wang	Secretary Dong
Zhang Tao	Executives
Mu Jing Wei	Director
Li Xiu Hai	Directors, executives
Zhang Lian Xin	Supervisors
Han Jing	Independent director
Wang Guo Ming	Directors, executives
Wang Chong Bang	Executives
Liu Yi Shan	Director
Li Qing Wei	Independent director
Mu Lai An	Director
Zhu Ying Jun	Executives
Chang Qing Ling	Supervisors
Zhang Peng	Director

Shanghai Kaibao Pharmaceutical Co (SZSE:300039) Headlines

No Headlines